Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

AACR 2023 | ATOMIC-Meso: pegargiminase in malignant pleural mesothelioma

Peter Szlosarek, MD, PhD, Barts Cancer Institute, London, UK, discusses findings from the Phase II/III ATOMIC-Meso trial (NCT02709512) of pegargiminase with chemotherapy in patients with non-epithelioid pleural mesothelioma. Patients were randomized to receive either pegargiminase or placebo with chemotherapy, and overall survival (OS) and progression-free survival (PFS) were the primary and secondary endpoints respectively. Both the endpoints were successfully met, and an encouraging safety profile was additionally reported. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.